Effects of testosterone replacement therapy withdrawal and re-treatment in hypogonadal elderly men upon obesity, voiding function and prostate safety parameters

References

• Lunenfeld B, Mskhalaya G, Zitzmann M, et al. Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men. Aging Male 2015;18:5–15
   PubMed Web of Science ®Google Scholar
• Wang C, Nieschlag E, Swerdloff RS, et al. ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male 2009;12:5–12
   PubMed Web of Science ®Google Scholar
• Brooke JC, Walter DJ, Kapoor D, et al. Testosterone deficiency and severity of erectile dysfunction are independently associated with reduced quality of life in men with type 2 diabetes. Andrology 2014;2:205–11
   PubMed Web of Science ®Google Scholar
• Donnell RF. Benign prostate hyperplasia: a review of the year’s progress from bench to clinic. Curr Opin Urol 2011;21:22–6
   PubMed Web of Science ®Google Scholar
• Schatzl G, Madersbacher S, Haitel A, et al. Associations of serum testosterone with microvessel density, androgen receptor density and androgen receptor gene polymorphism in prostate cancer. J Urol 2003;169:1312–5
   PubMed Web of Science ®Google Scholar
• Yassin DJ, El Douaihy Y, Yassin AA, et al. Lower urinary tract symptoms improve with testosterone replacement therapy in men with late-onset hypogonadism: 5-year prospective, observational and longitudinal registry study. World J Urol 2014;32:1049–54
   PubMed Web of Science ®Google Scholar
• Rohrmann S, Smit E, Giovannucci E, Platz EA. Associations of obesity with lower urinary tract symptoms and noncancer prostate surgery in the Third National Health and Nutrition Examination Survey. Am J Epidemiol 2004;159:390–7
   PubMed Web of Science ®Google Scholar
• Seim A, Hoyo C, Ostbye T, Vatten L. The prevalence and correlates of urinary tract symptoms in Norwegian men: the HUNT study. BJU Int 2005;96:88–92
   PubMed Web of Science ®Google Scholar
• Laven BA, Orsini N, Andersson SO, et al. Birth weight, abdominal obesity and the risk of lower urinary tract symptoms in a population based study of Swedish men. J Urol 2008;179:1891–5
   PubMed Web of Science ®Google Scholar
• De Nunzio C, Aronson W, Freedland SJ, et al. The correlation between metabolic syndrome and prostatic diseases. Eur Urol 2012;61:560–70
   PubMed Web of Science ®Google Scholar
• Kelly DM, Jones TH. Testosterone and obesity. Obes Rev 2015;16:581–606
   PubMed Web of Science ®Google Scholar
• Schroeder ET, Zheng L, Yarasheski KE, et al. Treatment with oxandrolone and the durability of effects in older men. J Appl Physiol (1985) 2004;96:1055–62
   PubMed Web of Science ®Google Scholar
• Schroeder ET, Zheng L, Ong MD, et al. Effects of androgen therapy on adipose tissue and metabolism in older men. J Clin Endocrinol Metab 2004;89:4863–72
   PubMed Web of Science ®Google Scholar
• Corrales JJ, Almeida M, Miralles JM, Orfao A. Persistence of androgenic effects on the production of proinflammatory cytokines by circulating antigen-presenting cells after withdrawal of testosterone treatment in aging type 2 diabetic men with partial androgen deficiency. Fertil Steril 2009;92:311–9
   PubMed Web of Science ®Google Scholar
• Francomano D, Bruzziches R, Barbaro G, et al. Effects of testosterone undecanoate replacement and withdrawal on cardio-metabolic, hormonal and body composition outcomes in severely obese hypogonadal men: a pilot study. J Endocrinol Invest 2014;37:401–11
   PubMed Web of Science ®Google Scholar
• Bhasin S, Pencina M, Jasuja GK, et al. Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the Framingham Heart Study and applied to three geographically distinct cohorts. J Clin Endocrinol Metab 2011;96:2430–9
   PubMed Web of Science ®Google Scholar
• Saad F, Haider A, Doros G, Traish A. Long-term treatment of hypogonadal men with testosterone produces substantial and sustained weight loss. Obesity (Silver Spring) 2013;21:1975–81
   PubMed Web of Science ®Google Scholar
• Yassin A, Doros G. Testosterone therapy in hypogonadal men results in sustained and clinically meaningful weight loss. Clin Obes 2013;3:73–83
   PubMedGoogle Scholar
• Francomano D, Ilacqua A, Bruzziches R, et al. Effects of 5-year treatment with testosterone undecanoate on lower urinary tract symptoms in obese men with hypogonadism and metabolic syndrome. Urology 2014;83:167–73
   PubMed Web of Science ®Google Scholar
• Francomano D, Lenzi A, Aversa A. Effects of five-year treatment with testosterone undecanoate on metabolic and hormonal parameters in ageing men with metabolic syndrome. Int J Endocrinol 2014;2014:527470
   PubMed Web of Science ®Google Scholar
• Haider A, Saad F, Doros G, Gooren L. Hypogonadal obese men with and without diabetes mellitus type 2 lose weight and show improvement in cardiovascular risk factors when treated with testosterone: an observational study. Obes Res Clin Pract 2014;8:e339–49
   PubMed Web of Science ®Google Scholar
• Saad F, Yassin A, Doros G, Haider A. Effects of long-term treatment with testosterone on weight and waist size in 411 hypogonadal men with obesity classes I-III: observational data from two registry studies. Int J Obes (Lond) 2015. [Epub ahead of print]. doi:10.1038/ijo.2015.139
   Web of Science ®Google Scholar
• Yassin A, Almehmadi Y, Saad F, et al. Effects of intermission and resumption of long-term testosterone replacement therapy on body weight and metabolic parameters in hypogonadal in middle-aged and elderly men. Clin Endocrinol (Oxf) 2015. [Epub ahead of print]. doi:10.1111/cen.12936
   PubMed Web of Science ®Google Scholar
• Yassin AA, El-Sakka AI, Saad F, Gooren LJ. Lower urinary-tract symptoms and testosterone in elderly men. World J Urol 2008;26:359–64
   PubMed Web of Science ®Google Scholar
• Yassin DJ, Doros G, Hammerer PG, Yassin AA. Long-term testosterone treatment in elderly men with hypogonadism and erectile dysfunction reduces obesity parameters and improves metabolic syndrome and health-related quality of life. J Sex Med 2014;11:1567–76
   PubMed Web of Science ®Google Scholar
• Giltay EJ, Haider A, Saad F, Gooren LJ. C-reactive protein levels and ageing male symptoms in hypogonadal men treated with testosterone supplementation. Andrologia 2008;40:398–400
   PubMed Web of Science ®Google Scholar
• Morgentaler A. Testosterone therapy in men with prostate cancer: scientific and ethical considerations. J Urol 2013;189:S26–33
   PubMed Web of Science ®Google Scholar
• Haider A, Zitzmann M, Doros G, et al. Incidence of prostate cancer in hypogonadal men receiving testosterone therapy: observations from 5-year median followup of 3 registries. J Urol 2015;193:80–6
   PubMed Web of Science ®Google Scholar
• Dohle GR, Arver S, Bettocchi C, et al EAU Guidelines on Male Hypogonadism. Available from: http://uroweb.org/guideline/male-hypogonadism [last accessed 25 Jun 2015]
   Google Scholar
• Grober ED. Testosterone deficiency and replacement: myths and realities. Can Urol Assoc J 2014;8:S145–7
   PubMed Web of Science ®Google Scholar